PubMed Daily Triage — 2026-11-07
Run ID: 2026-11-07-attempt1-20261107T100000Z | Attempt: 1 of 3
Generated: 2026-11-07T10:00:00Z
⚠️ Run Notes
CRDT Propagation Lag — 48-Hour Window Expansion Applied
ESearch for 2026/11/07[CRDT] returned count=0 across all 10 watchlist topics and sentinel at 10:00 UTC. ESummary probes confirmed the PubMed database tops out near PMID 42995150 (entrez date 2026-11-06 22:43 UTC); no articles with CRDT 2026-11-07 existed at run time. Pipeline rule applied: fewer than 5 relevant records → expanded to 48-hour window (2026/11/06[CRDT] : 2026/11/07[CRDT]). All 122 unique candidate PMIDs bear CRDT date 2026-11-06.
Summary Statistics
| Topic | Raw | Candidates | HIGH | STANDARD | LOW/Excl |
|---|---|---|---|---|---|
| Hematologic malignancies | 72 | 15 | 2 | 2 | 11 |
| CBC/ML hematology diagnostics | 1 | 1 | 0 | 0 | 1 (FP) |
| Early cancer detection / liquid biopsy | 32 | 15 | 2 | 1 | 12 |
| AI/ML clinical diagnostics | 34 | 15 | 2 | 0 | 13 |
| Precision oncology / genomic medicine | 42 | 15 | 3 | 1 | 11 |
| Novel therapeutics / immunotherapy / CAR-T | 131 | 15 | 0 | 1 | 14 |
| Cardiovascular-metabolic / GLP-1 / SGLT2 | 90 | 15 | 0 | 3 | 12 |
| Aging / longevity / population health | 50 | 15 | 1 | 2 | 12 |
| Rare diseases / high unmet need | 16 | 15 | 0 | 1 | 14 |
| Sentinel | 156 | 10 | 1 | 0 | 9 |
| TOTAL | 624 | 131* | 11 | 11 | 109 |
* 131 candidates before deduplication → 122 unique PMIDs; 21 articles included in output array.
* Sentinel PMID 42993853 counted as HIGH in both T5 and T8 (shared article).
🔴 HIGH Priority Articles (score 8–9)
1. PMID 42993180 — Urinary GAGome Multi-Cancer Risk Prediction · Score 9
Journal: Cancer Epidemiol Biomarkers Prev | Topic: Early Cancer Detection
Design: Case-cohort, n=5,436 asymptomatic adults, Lifelines Cohort (Netherlands)
Key finding: Urinary glycosaminoglycan profiles (GAGomes) predicted 5-year incident cancer risk with HR=1.66 per SD (36% variance explained); Very High risk group had 32% 5-year risk; targeting High-risk group captures 54% of incident cancers at 17% FPR.
Why it matters: Novel non-invasive multi-cancer biomarker from urine, validated in a large population cohort; potentially extends cancer screening beyond age/tobacco guideline thresholds.
2. PMID 42993171 — Mesothelioma MTAP Loss & ICI Response · Score 9
Journal: Clinical Cancer Research | Topic: Precision Oncology
Design: WGS + RNA-seq discovery cohort (n=52) + nationwide C-CAT validation
Key finding: MTAP loss associated with higher CD8+ T-cell infiltration, greater TCR diversity, and higher ICI response rate in MPM; immune-active TME (high TCR diversity, CD8+ infiltration, M1 macrophages) predicted response to nivolumab+ipilimumab.
Why it matters: First multiomics study identifying MTAP loss as a candidate ICI biomarker in this rare, high-unmet-need cancer; Clin Cancer Res with dual-cohort validation.
3. PMID 42994396 — Real-World ctDNA Adoption in Bladder Cancer · Score 8
Journal: ESMO Open | Topic: Early Cancer Detection / Liquid Biopsy
Design: Retrospective cohort, n=4,533 MIBC patients, Flatiron Health database
Key finding: ctDNA testing increased 16%/quarter; detectable ctDNA associated with more adjuvant therapy (unadjusted RR 2.15) but attenuated after adjustment (adj RR 1.34, NS); pathologic risk stage dominant predictor (adj RR 9.45).
Why it matters: Largest real-world study of ctDNA adoption in MIBC; reveals pathologic risk currently overrides ctDNA result in clinical decisions—important calibration for liquid biopsy clinical translation.
4. PMID 42992124 — ML Outperforms ELN2024 in AML Prognosis · Score 8
Journal: ESMO Real World Data and Digital Oncology | Topic: Hematologic Malignancies / CBC-ML
Design: Retrospective multicenter ML cohort, n=785 AML patients, Danish registry
Key finding: ML models achieved C-index >0.75 vs ~0.57 for ELN2024 in non-intensively treated AML; clinical variables had greatest feature importance; adding genetic features did not consistently improve performance.
Why it matters: Multicenter Danish cohort demonstrating ML can improve AML prognosis over guidelines; clinical features (not genomics alone) drive the gain—challenges genomic-centric stratification assumptions.
5. PMID 42994757 — Risk-Adapted Donor Selection in AML · Score 8
Journal: Transplantation and Cellular Therapy | Topic: Hematologic Malignancies
Design: Retrospective registry cohort, n=1,963 AML patients, Taiwan HSCT registry 2009–2025, doubly-robust IPTW
Key finding: MUD associated with better OS vs MMUD and HID through lower NRM; in high/very-high-risk AML, MUD achieved 42.7% vs 28.5% 3-year OS; risk-adapted donor selection supported by causal mediation analysis.
Why it matters: Largest AML HSCT donor-selection study in Asian ATG-prevalent practice; directly practice-changing for high-risk AML—prioritize MUD, use GRFS to guide lower-risk donor choice.
6. PMID 42994434 — Foundation Models & VLMs in MRI · Score 8
Journal: Cell Reports Medicine | Topic: AI/ML Clinical Diagnostics
Design: Systematic review, 35 studies
Key finding: Neuroimaging leads FM/VLM adoption (diagnostic classification most mature); segmentation and outcome prediction show promise; report generation limited by poor clinical fidelity; key barriers: heterogeneous MRI acquisition, limited paired image-text datasets.
Why it matters: First comprehensive systematic review of FMs and VLMs in MRI; published in Cell Reports Medicine; maps the landscape and identifies translation bottlenecks for researchers and clinicians.
7. PMID 42994624 — MONKEY Challenge: DL for Kidney Transplant Biopsy Banff Scoring · Score 8
Journal: Laboratory Investigation | Topic: AI/ML Clinical Diagnostics
Design: Multicenter ML challenge, 118 biopsies (131,000+ annotated cells) + 180-biopsy independent validation
Key finding: Top DL models achieved F1=0.75 overall (lymphocytes F1=0.78, monocytes F1=0.47); strong correlation with consensus Banff lesion scoring in independent cohort.
Why it matters: First multicenter PAS-based benchmark for Banff-aligned AI classification in transplant pathology; establishes foundation for standardized AI tools in clinical kidney transplant evaluation.
8. PMID 42994867 — BRAF V600E mCRC Network Meta-Analysis · Score 8
Journal: Medicine (Baltimore) | Topic: Precision Oncology
Design: Network meta-analysis, 4 trials, n=922 patients
Key finding: All encorafenib-based regimens improved PFS over irinotecan+cetuximab; encorafenib+cetuximab had fewest G≥3 AEs (OR 0.67); no significant difference between EBC and EC on PFS or OS.
Why it matters: Positions encorafenib+cetuximab as reference standard for previously treated BRAF V600E-mutant mCRC with best tolerability; clarifies that adding binimetinib confers no significant advantage with added toxicity.
9. PMID 42993853 — Age Reshapes Melanoma Driver Mutation Selection · Score 8
Journal: Science Advances | Topic: Precision Oncology / Aging
Design: Computational genomic analysis, n=5,472 melanomas
Key finding: Aging alters driver mutation selection more than mutation rates: BRAF V600E advantage declines precipitously with age; NRAS Q61 mutations gain advantage; TERT promoter mutations become more frequent but less advantageous with age.
Why it matters: Genuinely novel population-level finding in Sci Adv; challenges age-agnostic BRAF biomarker use; motivates age-stratified biomarker and therapy evaluation in melanoma.
10. PMID 42990844 — ICI + Ultra-Hypofractionated RT Safety Meta-Analysis · Score 8
Journal: Clinical and Translational Radiation Oncology | Topic: Sentinel
Design: Systematic review and meta-analysis, 2,057 patients, 53 trials (52 phase I-II + 1 phase III)
Key finding: No consistent signal of increased systemic toxicity with concomitant ICI + U-HFRT vs ICI monotherapy; G3-4 colitis 1.1%, pneumonitis 0.5%; mOS 10.2 months across cancer types.
Why it matters: Largest safety meta-analysis for ICI + ablative RT combination; safety reassurance directly enables clinical use and future trial design.
🟡 STANDARD Priority Articles (score 5–7)
| PMID | Score | Topic | Title (abbreviated) |
|---|---|---|---|
| 42992312 | 7 | Hematologic malignancies | CLL/SLL real-world BTKi tolerability (n=584; 51.2% discontinued by 24m, mainly AEs) |
| 42992956 | 7 | Hematologic malignancies | B-cell markers + cancer risk in HIV (CXCL13 OR 2.36 for cancer; lymphoma OR 9.92) |
| 42993579 | 7 | Aging / longevity | "Simply aging" PNAS perspective (Gladyshev; deleteriome framework) |
| 42993913 | 7 | Aging / longevity | Undiagnosed dementia Brazil Neurology (5-year trend; 5.53%→3.86%; equity gains) |
| 42995003 | 7 | Cardiovascular-metabolic | Maternal CV risk → offspring CVD (Cardiovasc Res, ILEP-endorsed; 2× offspring risk) |
| 42990653 | 7 | Novel therapeutics | NR2F6 T-cell checkpoint limits CAR-T potency (iScience; CRISPR validation; preclinical) |
| 42993741 | 6 | Precision oncology | RPL22 mutation favorable prognosis in dMMR endometrial cancer (n=250; HR=0.14) |
| 42990688 | 6 | Rare diseases | Watershed-DL rare variant prioritization medRxiv (61.4% more variants, 60× ClinVar enrichment) |
| 42994978 | 5 | Cardiovascular-metabolic | Semaglutide secondary CV prevention Drug Ther Bull (title-only; conservative cap) |
| 42993440 | 5 | Early cancer detection | ctDNA in resectable ESCC narrative review (MRD detection; prospective trials needed) |
| 42991981 | 5 | Cardiovascular-metabolic | Tirzepatide in lipoedema cohort (n=49; 100% ≥30% improvement; not weight-loss-dependent) |
Per-Topic Summary
Hematologic Malignancies
4 articles included. 2 HIGH: AML ML prediction (42992124) and AML risk-adapted donor selection (42994757). 2 STANDARD: CLL BTKi real-world cohort (42992312) and B-cell markers + cancer risk in HIV (42992956). 11 excluded: 1 erratum, 5 preclinical/in vitro, 2 ESummary-only off-topic, 3 low-relevance.
CBC/ML Hematology Diagnostics
0 articles included. 1 candidate (PMID 42993385) confirmed false positive on ESummary review: article is about cancer screening predictors in a multiethnic Southeast Asian population, not CBC morphology + ML in hematology. No genuine T2 articles indexed on 2026-11-06.
Early Cancer Detection / Liquid Biopsy
3 articles included. 2 HIGH: multi-cancer GAGome (42993180) and ctDNA bladder ESMO Open (42994396). 1 STANDARD: ctDNA ESCC review (42993440). 12 excluded: 4 false positives (Lyme cfDNA, education, joint infection, prenatal cfDNA), 4 peripheral relevance, 1 Letter pub type excluded.
AI/ML Clinical Diagnostics
2 articles included. 2 HIGH: VLM/MRI systematic review Cell Reports Medicine (42994434) and MONKEY kidney biopsy challenge (42994624). 13 excluded: 1 false positive (music synthesis DL), 4 dental/non-core AI, 5 ESummary-only low-relevance, 3 peripheral.
Precision Oncology / Genomic Medicine
4 articles included. 3 HIGH: mesothelioma multiomics (42993171), BRAF V600E mCRC NMA (42994867), age + melanoma drivers (42993853). 1 STANDARD: RPL22 endometrial cancer (42993741). 11 excluded: 4 ESummary-only reviews, 2 preclinical/low-impact, 1 case report, 1 ESummary unavailable (42993846).
Novel Therapeutics / Immunotherapy / CAR-T
1 article included. 0 HIGH, 1 STANDARD: NR2F6 T-cell checkpoint/CAR-T (42990653). 14 excluded: 1 retraction, 1 false positive, 7 preclinical only/no abstract, 5 ESummary-only low-relevance. No first-in-human or Phase III trials returned in this window.
Cardiovascular-Metabolic / GLP-1 / SGLT2
3 articles included. 0 HIGH, 3 STANDARD: maternal CV offspring (42995003), semaglutide Drug Ther Bull (42994978, title-only cap), tirzepatide lipoedema (42991981). 12 excluded: 2 pub type exclusions (erratum, comment), 5 ESummary-only low-relevance, 5 peripheral cardiometabolic.
Aging / Longevity / Population Health
3 articles included. 1 HIGH (shared with T5): age reshapes melanoma drivers (42993853). 2 STANDARD: "Simply aging" PNAS (42993579) and undiagnosed dementia Brazil Neurology (42993913). 12 excluded: 5 off-topic false positives, 4 highly peripheral, 3 ESummary-only low-relevance.
Rare Diseases / High Unmet Need
1 article included. 0 HIGH, 1 STANDARD: Watershed-DL rare variant prioritization medRxiv preprint (42990688; cap applied). 14 excluded: 5 not genuine rare disease (sepsis, musculoskeletal, military health, hospital registry), 3 medRxiv preprints (Dyggve-Melchior-Clausen, long-read RNA-seq, A53E Parkinson), 2 comment/pub type exclusion, 4 off-topic reassigned or false positive.
Sentinel
1 article included. 1 HIGH: ICI + ultra-hypofractionated RT meta-analysis (42990844). 9 excluded: 2 ESummary metadata truncated (PMIDs from batch 24-25), 4 off-topic (penicillin allergy, tobacco, spine surgery, vertebroplasty RCT), 2 low-signal, 1 false positive.
Scoring Rubric Reference
| Axis | Max |
|---|---|
| novelty_relevance | 3 |
| design_quality | 2 |
| population_or_unmet_need | 2 |
| clinical_relevance | 3 |
| Total | 10 |
Pipeline priority: HIGH = score 8–10 (peer-reviewed original research or high-impact review) | STANDARD = 5–7 | LOW = 0–4
Caps: Case reports ≤4; preprints ≤6; title-only/no-abstract ≤5; preclinical in vitro ≤7
Digest generated by PubMed Triage Pipeline v1.3 · Attempt 1 of 3 · 2026-11-07